Indium In-111 satumomab pendetide

Indium In-111 satumomab pendetide Overview

Indium In-111 satumomab pendetide is a diagnostic radiopharmaceutical and targeted monoclonal antibody historically used in clinical radiology to image extrahepatic malignant cancers. Chemically, it consists of the murine monoclonal antibody Satumomab (which targets tumor-associated glycoprotein 72) conjugated to the chelator pentetic acid (DTPA) and a tripeptide linker (glycine-L-tyrosine-L-lysine). This conjugated structure firmly chelates the radioactive isotope Indium-111, allowing for precise radioimaging of targeted tumors. While once marketed under the trade name OncoScint, it is no longer commercially available for clinical use.

What Is Indium In-111 satumomab pendetide and How Does It Work?

Indium In-111 satumomab pendetide functions as a targeted diagnostic imaging agent. The murine monoclonal antibody portion (Satumomab) selectively binds to tumor-associated glycoprotein 72 (TAG-72), an antigen highly expressed on the cell surface of various human adenocarcinomas, including colorectal and ovarian tumors.

By binding selectively to these malignant cells, the antibody successfully targets the attached Indium-111 radioisotope directly to the tumor site. The gamma radiation emitted by the Indium-111 isotope can then be detected and mapped using specialized gamma camera imaging techniques, allowing physicians to locate and determine the extent of extrahepatic malignant disease.

Is Indium In-111 satumomab pendetide FDA Approved?

Indium In-111 satumomab pendetide (marketed under the trade name OncoScint) was originally approved by the United States Food and Drug Administration (FDA) in December 1992 as a diagnostic imaging agent. However, it was subsequently discontinued and withdrawn from the commercial market in December 2002 and is no longer available for clinical use.

What Is Indium In-111 satumomab pendetide Used For?

• Used historically for the diagnostic radioimaging and localization of extrahepatic malignant cancers.
• Specifically indicated for determining the extent and location of known colorectal and ovarian tumors to guide surgical or therapeutic interventions.

Before Taking Indium In-111 satumomab pendetide: Contraindications & Precautions

Because this agent contains murine (mouse) proteins and a radioactive isotope, its administration carried specific immunological and radiological risks. It was contraindicated in patients with known severe hypersensitivity to murine proteins. Repeated administration was generally avoided due to the high risk of patients developing human anti-murine antibodies (HAMA).

Who Should Not Take Indium In-111 satumomab pendetide?

• Individuals with a documented severe hypersensitivity to murine proteins, Indium-111, or any formulation components.
• Patients who previously received murine monoclonal antibodies and developed significant HAMA titers.

Indium In-111 satumomab pendetide, Pregnancy & Fertility

As a radiopharmaceutical, Indium In-111 satumomab pendetide carried inherent risks of fetal radiation exposure. Its use in pregnant women was strictly contraindicated unless the critical diagnostic information was absolutely necessary and could not be obtained via non-radioactive imaging modalities. Nursing mothers were required to discontinue breastfeeding to prevent the transfer of the radioactive isotope to the infant.

Tell Your Doctor Before Taking Indium In-111 satumomab pendetide

Before receiving any radiolabeled antibody, patients had to disclose any prior diagnostic or therapeutic procedures involving murine (mouse) antibodies, as this significantly increased the risk of severe allergic reactions or HAMA formation.

Indium In-111 satumomab pendetide Dosage & Administration

Administered strictly in specialized nuclear medicine facilities by trained and licensed medical personnel.

Standard Indium In-111 satumomab pendetide Dosing

• Administered as a single, one-time diagnostic dose containing a highly specific measured amount of radioactivity.
• Gamma camera imaging was generally performed 48 to 72 hours post-injection to allow for optimal tumor targeting and background blood clearance.

How Indium In-111 satumomab pendetide Is Administered

• Administered strictly via intravenous (IV) injection.
• Patients were often premedicated or monitored closely during the infusion to manage potential hypersensitivity reactions.

Indium In-111 satumomab pendetide Clinical Efficacy & Research

During its market lifespan, Indium In-111 satumomab pendetide demonstrated clinical utility in detecting recurrent colorectal and ovarian carcinomas, particularly in extrahepatic locations like the pelvis and abdomen, where standard CT scanning was sometimes less sensitive. However, its tendency to induce HAMA responses restricted its utility for repeat imaging, which contributed to its eventual replacement by newer diagnostic modalities and less immunogenic imaging agents.

Indium In-111 satumomab pendetide Side Effects & Safety Profile

The safety profile involved both immunological reactions to the foreign antibody and standard radiological precautions.

Common Indium In-111 satumomab pendetide Side Effects

• Mild, transient fever or chills following the intravenous infusion.
• Pruritus (itching) or localized rash.
• Development of human anti-murine antibodies (HAMA) altering future diagnostic tests.

Serious Indium In-111 satumomab pendetide Adverse Events

• Immediate systemic hypersensitivity reactions, including severe anaphylaxis, bronchospasm, and hypotension.
• Unintended radiation exposure to healthy tissues, particularly the liver and spleen where the antibody conjugate is naturally metabolized.

Managing Indium In-111 satumomab pendetide Side Effects

Administration was always performed in a controlled clinical environment equipped with emergency resuscitation equipment, intravenous epinephrine, and antihistamines to rapidly manage acute anaphylaxis.

Indium In-111 satumomab pendetide Drug Interactions & What to Avoid

No significant traditional drug-drug interactions were established. However, elevated HAMA levels from prior treatments could bind the drug prematurely in the bloodstream, altering its biodistribution and decreasing imaging efficacy.

Indium In-111 satumomab pendetide Drug-Drug Interactions

• Concomitant use with other murine-based biological therapies was carefully managed to prevent compounded HAMA formation.
• No specific traditional small-molecule drug interactions were identified.

Indium In-111 satumomab pendetide, Food & Alcohol

No specific interactions with food or alcohol existed. Patients typically did not require dietary restrictions prior to administration, though specific bowel preparation protocols were sometimes utilized to improve abdominal imaging clarity.

Indium In-111 satumomab pendetide Missed Dose, Overdose & Storage

Because the agent was administered as a single, scheduled dose by a nuclear medicine physician, standard missed dose rules did not apply.

Missed Dose of Indium In-111 satumomab pendetide

If a patient missed their scheduled injection, the nuclear imaging appointment had to be completely rescheduled and a new radioactive dose ordered.

Indium In-111 satumomab pendetide Overdose & Emergency

Overdose was highly unlikely due to strict laboratory calibration of the radioactive dose prior to administration. If an excess of radioactivity was inadvertently administered, management focused on accelerating the clearance of the isotope through aggressive hydration and frequent urination.

How to Store Indium In-111 satumomab pendetide

Stored exclusively in shielded, heavily regulated radiopharmacies at specified controlled temperatures prior to extemporaneous labeling and immediate clinical use.

Indium In-111 satumomab pendetide Patient Management & Monitoring

Extensive monitoring was required during and immediately following the infusion to ensure radiological and immunological safety.

Tests Before Starting Indium In-111 satumomab pendetide

• Assessment of baseline HAMA levels, particularly if the patient had a history of receiving murine antibodies.
• Routine assessment of vital signs.

Monitoring During Indium In-111 satumomab pendetide Treatment

Patients were continuously monitored for signs of hypersensitivity, changes in blood pressure, and respiratory distress throughout the infusion and for a designated observation period afterward.

Indium In-111 satumomab pendetide Do’s and Don’ts

• Do inform your doctor of any previous exposure to mouse-based antibodies.
• Do drink plenty of fluids after the scan to help flush the radioactive tracer from your body.
• Do not undergo subsequent murine antibody treatments without ensuring your HAMA levels have been tested.
• Do not breastfeed after receiving this radioactive diagnostic agent without consulting your doctor.

Frequently Asked Questions

References

• DrugBank Database – Indium In-111 satumomab pendetide Clinical and Pharmacological Profile
• The structure and reference rules are documented in the “Gemini Chat for Reviewing and Generation.md” file.

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, diagnostic procedures, or radiological exposure.